Abbott Laboratories
Search results
AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives. Our company. 2016 Dow Jones Sustainability World Index. AbbVie was named the Biotechnology Industry Leader for our responsible economic, environmental and social performance. Pause.
AbbVie In Singapore. People. Passion. Possibilities. ®. At AbbVie, we combine advanced science, expertise and passion to solve. serious health issues and have a remarkable impact on people’s lives. We are. committed to improving health care in markets where we operate. Passionate about our work.
Jan 25, 2024 · This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network. Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide.
Jan 26, 2024 · New York-listed AbbVie strengthened its manufacturing capabilities by breaking ground on a new $223 million expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.
When we became our own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company. We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech.
Jan 26, 2024 · AbbVie’s Singapore plant produces small molecules and biologics, serving markets around the world. The new investment is pegged to add 24,000 liters of biologics drug-substance capacity,...
Apr 13, 2021 · Apr 13, 2021, 04:00 AM. Established in 2013, biopharmaceutical giant AbbVie's high-performing culture has been reflected in a strong financial track record, and quick expansion over a short...
Sep 28, 2016 · AbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline. - New site to expand the company's global operations for small molecule and biologics manufacturing. - Marks AbbVie's first manufacturing presence in Asia.
Jan 26, 2024 · AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new...
5 days ago · AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at...
